A Novel Prognostic Model of NPI for Risk-Predicting and Clinical Decision-making in Diffuse Large B-Cell Lymphoma in the Rituximab Era
- Conditions
- Diffuse Large B Cell Lymphoma
- Registration Number
- NCT04624971
- Lead Sponsor
- Sun Yat-sen University
- Brief Summary
The purpose of this study is to determine the predictive value of a model of Nomogram Prognostic Index (NPI) in patients with Diffuse Large B cell lymphoma.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 2000
Inclusion Criteria
- histologically confirmed diagnosis of CD20+ DLBCL
Exclusion Criteria
- primary central nervous system lymphoma
- "double-hit" lymphoma
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Overall survival 5-year
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (3)
Guangdong General Hospital
🇨🇳Guangzhou, Guangdong, China
Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University,
🇨🇳Guangzhou, China
Sun Yat-sen Universitiy Cancer Center, Sun Yat-Sen University,
🇨🇳Guangzhou, China